Furthermore, elevated EZH2 levels in lung cancer are associated with reduced responsiveness to treatment, complicating disease management (Sun et al., 2014; Sun et al., 2016; Chen et al., 2020; Yang et al., 2021). This evidence concerns the gene EZH2 and lung carcinoma.